ClinicalTrials.gg
RecruitingNCT06156683Updated Aug 1, 2024

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

An observational study in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Switzerland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,500
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 23 under way, 6 of them phase 3. Multiple Sclerosis · Novartis.

Planned enrollment
9th of 41
1,500 · median 312
Started
2024
with 8 others
Observational
41 of 106
7 open now
Primary completion
2028-02
later than 12 of 22 live
Registered
83rd of 106
by date

Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 9th largest by planned enrollment of the 41 observational ones that give a count, is one of 9 that started in 2024, is one of 41 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 83rd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

9 of the 106 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Multiple Sclerosis by Novartis, or all of them as a file.
02

Study summary

The study is an observational retrospective cohort study using longitudinal secondary data. Pregnant women with MS are assessed for exposure to Kesimpta and other MS disease modifying drugs (MSDMD) and followed up for adverse pregnancy and infant outcomes.

Read the detailed description

Outcomes among Kesimpta exposed pregnancies are compared primarily to MSDMD-exposed pregnancies and secondarily to MSDMD-unexposed pregnancies.

The main research question is to determine whether the exposure during pregnancy to Kesimpta increases the risk of adverse pregnancy and infant outcomes in women with MS.

The risk period is defined as the 1st trimester of pregnancy for analyses of Major congenital malformations and the entire duration of pregnancy for all other outcomes.

The data for this study is retrieved from data sources from Denmark, Sweden, and the US, based on an assessment of feasibility.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Kesimpta
  • ofatumumab
  • real world data
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The overall study population consists of women with MS with a recorded pregnancy outcome during the inclusion period. Pregnancies exposed to MSDMDs with a known teratogenic effect or non-MSDMDs with a known moderate to high teratogenic effect are excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following overall criteria for study inclusion are applied:

  • Pregnancy with a recorded start and end of pregnancy outcome (live birth, spontaneous abortion, elective termination, stillbirth, or ectopic pregnancy) during the inclusion period
  • Age 18-49 years at index date
  • A diagnosis of MS before the index date. This inclusion criterion is based on diagnosis codes, as recorded in the different data sources
  • Availability of information on exposure to MSDMDs and maternal baseline characteristics for a minimum of 12 months before the index date

In addition, the following outcome and objective specific inclusion criteria are applied:

  • For analyses of MCMs in live births (primary objective): pregnancy ending in at least one live birth
  • For analyses of spontaneous abortion, elective termination of pregnancy, stillbirth, preeclampsia, eclampsia (secondary objectives): pregnancy ending in at least one live birth, spontaneous abortion, elective termination, stillbirth, or ectopic pregnancy
  • For analyses of preterm birth, SGA (secondary objectives): pregnancy ending in at least one live birth
  • For analyses of MCMs among live births, spontaneous abortions, stillbirths, and elective terminations (exploratory objective): pregnancy ending in at least one live birth, spontaneous abortion, still birth, or elective termination
  • For analyses of neonatal infection: live newborn
  • For analyses of SII: newborn alive at 29 days after birth

Exclusion criteria

Exclusion Criteria:

The following overall criteria for exclusion are applied:

  • Pregnancy exposed to a MSDMD that have a known teratogenic effect, determined based on the date of prescription, estimated supply duration, and the drug-specific window of clearance
  • Pregnancy exposed to a non-MSDMD that have a known moderate to high teratogenic effect, determined based on the date of prescription, estimated supply duration, and the drug-specific window of clearance

The following outcome specific exclusion criteria are applied:

  • For analyses of MCMs and exploratory analyses of MCMs: pregnancies with a record of a chromosomal abnormality or a genetic syndrome
  • For analyses of preterm birth, pre-eclampsia, eclampsia and SGA, pregnancies involving multiples
  • For Kesimpta and MSDMD-exposed cohorts: pregnancies not exposed during the outcome specific risk period
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Kesimpta-exposed

    exposure to Kesimpta during the risk period

    Other: Multiple sclerosis disease modifying drug

  • MSDMD-exposed

    exposure to at least one Multiple sclerosis disease modifying drug (MSDMD) (other than Kesimpta) during the risk period

    Other: Multiple sclerosis disease modifying drug

  • MSDMD-unexposed

    no exposure to Kesimpta or any other Multiple sclerosis disease modifying drug (MSDMD) during the risk period

    Other: Multiple sclerosis disease modifying drug

Interventions

  • OtherMultiple sclerosis disease modifying drug

    There is no treatment allocation. Women with multiple sclerosis with a recorded pregnancy outcome during the inclusion period will be recruited.

06

What researchers measure

Primary outcomes

  1. Number of major congenital malformations (MCM) among live births

    The primary outcome of interest concerns MCMs occurring in pregnancies ending in at least one live birth. MCMs are defined as defects that have either cosmetic or functional significance to the child (e.g., a cleft lip)

    Time frame: First year of life, up to 12 months

Secondary outcomes

  1. Number of participants with spontaneous abortions

    Also termed miscarriage, is defined as the unintended loss of an intrauterine pregnancy less than 20 weeks of gestation (\<20 weeks).

    Time frame: Up to 9 months

  2. Number of participants with elective termination of pregnancy

    Defined as the intentional termination of pregnancy at any time in gestation for any reason. When possible, reasons for elective termination are captured and classified as elective termination of pregnancy for fetal anomaly or for other reasons.

    Time frame: Up to 9 months

  3. Number of participants with stillbirths

    Defined as the unintended fetal death occurring at or after 20 weeks of gestation.

    Time frame: Up to 9 months

  4. Number of participants with preterm births

    Defined as live births less than 37 weeks of gestation (\<37 weeks). Elective caesarean deliveries or inductions prior to 37 completed weeks will be described separately.

    Time frame: Up to 9 months

  5. Number of participants with preeclampsia

    Preeclampsia is defined as the new-onset of hypertension with a systolic blood pressure greater than or equal to 140 mmHg and/or diastolic blood pressure greater than or equal to 90 mmHg at or after 20 weeks of gestation with proteinuria and/or endorgan dysfunction (renal dysfunction, liver dysfunction, central nervous system disturbances, pulmonary edema, and thrombocytopenia).

    Time frame: Up to 9 months

  6. Number of participants with eclampsia

    Eclampsia is defined as the new onset of generalized tonic-clonic seizures in a woman with preeclampsia

    Time frame: Up to 9 months

  7. Number of participants small for gestational age (SGA)

    Defined as a birth weight lower than the 10th percentile for gestational age and sex using the national standards in each study country in a live birth

    Time frame: Up to 9 months

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative Site
    Basel, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Feb 2028, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 5, 2023
StartActual
Jun 30, 2024
Primary completionEst.
Feb 1, 2028
CompletionEst.
Feb 1, 2028
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06156683
Responsible party
Sponsor
First posted
Dec 5, 2023
Start date
Jun 30, 2024
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Aug 1, 2024

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion